FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311736082> ?p ?o ?g. }

• W4311736082 abstract "Abstract Background The incidence of organisms with extended-spectrum beta-lactamases (ESBLs) is increasing. The data for using cefepime in ESBL-producing Enterobacterales infections is conflicting. More favorable outcomes are likely if minimum inhibitory concentrations (MICs) &lt; 2 mcg/mL. The aim of this study is to compare the efficacy of cefepime versus carbapenems for ESBL-producing, non-bloodstream Enterobacterales infections. Methods This study was a single-center retrospective cohort study of patients who received cefepime or a carbapenem for at least 72 hours for the definitive treatment of an ESBL-producing Enterobacterales non-bloodstream infection between Jan. 1, 2011 and Sept. 30, 2021. ESBL production was identified if the isolate either had a positive confirmatory ESBL test from VITEK 2 (bioMérieux) or phenotypic resistance to ceftriaxone. Isolates had to have a MIC &lt; 2 mcg/mL to cefepime or be susceptible to carbapenems. Isolates with a cefepime MIC 4-8 mcg/mL were not included due to likely higher rates of treatment failure. The primary endpoint was clinical failure, defined as persistence of symptoms requiring escalation of therapy or death. Descriptive statistics were used to compare groups. A univariate analysis and odds ratio was calculated for clinical outcomes. Results One hundred patients were included. Twenty-two patients received cefepime and 78 received a carbapenem. Table 1 describes patient characteristics and clinical outcomes. Most patients had a urinary tract infection (UTI) (94%). More patients receiving cefepime were admitted to the intensive care unit (40.9% versus 15.4%). Treatment with cefepime displayed higher rates of clinical failure when compared to treatment with carbapenems (13.6% versus 6.4%). Cohen’s d-test for clinical failure was 0.46, indicating a medium effect. Conclusion Based on our analysis, cefepime may have higher rates of clinical failure when compared to carbapenem treatment for ESBL-producing Enterobacterales. Most of our patients were treated for UTIs and the sample size for both arms were limited, particularly for the cefepime arm. Further research is needed to confirm the role of cefepime as a carbapenem-sparing option in the treatment of these drug-resistant infections. Disclosures Madeline King, PharmD, Shionogi: Honoraria|Tetraphase: speakers' bureau." @default.
• W4311736082 created "2022-12-28" @default.
• W4311736082 creator A5013872247 @default.
• W4311736082 creator A5014066546 @default.
• W4311736082 creator A5043579748 @default.
• W4311736082 creator A5083227197 @default.
• W4311736082 date "2022-12-01" @default.
• W4311736082 modified "2023-09-30" @default.
• W4311736082 title "647. Cefepime Versus Carbapenems for the Treatment of ESBL-producing <i>Enterobacterales</i> among Non-blood Isolates" @default.
• W4311736082 doi "https://doi.org/10.1093/ofid/ofac492.699" @default.
• W4311736082 hasPublicationYear "2022" @default.
• W4311736082 type Work @default.
• W4311736082 citedByCount "0" @default.
• W4311736082 crossrefType "journal-article" @default.
• W4311736082 hasAuthorship W4311736082A5013872247 @default.
• W4311736082 hasAuthorship W4311736082A5014066546 @default.
• W4311736082 hasAuthorship W4311736082A5043579748 @default.
• W4311736082 hasAuthorship W4311736082A5083227197 @default.
• W4311736082 hasBestOaLocation W43117360821 @default.
• W4311736082 hasConcept C126322002 @default.
• W4311736082 hasConcept C156957248 @default.
• W4311736082 hasConcept C2776376669 @default.
• W4311736082 hasConcept C2776520383 @default.
• W4311736082 hasConcept C2776685102 @default.
• W4311736082 hasConcept C2777050379 @default.
• W4311736082 hasConcept C2779443120 @default.
• W4311736082 hasConcept C2779631663 @default.
• W4311736082 hasConcept C501593827 @default.
• W4311736082 hasConcept C64778159 @default.
• W4311736082 hasConcept C71924100 @default.
• W4311736082 hasConcept C86803240 @default.
• W4311736082 hasConcept C89423630 @default.
• W4311736082 hasConcept C94665300 @default.
• W4311736082 hasConceptScore W4311736082C126322002 @default.
• W4311736082 hasConceptScore W4311736082C156957248 @default.
• W4311736082 hasConceptScore W4311736082C2776376669 @default.
• W4311736082 hasConceptScore W4311736082C2776520383 @default.
• W4311736082 hasConceptScore W4311736082C2776685102 @default.
• W4311736082 hasConceptScore W4311736082C2777050379 @default.
• W4311736082 hasConceptScore W4311736082C2779443120 @default.
• W4311736082 hasConceptScore W4311736082C2779631663 @default.
• W4311736082 hasConceptScore W4311736082C501593827 @default.
• W4311736082 hasConceptScore W4311736082C64778159 @default.
• W4311736082 hasConceptScore W4311736082C71924100 @default.
• W4311736082 hasConceptScore W4311736082C86803240 @default.
• W4311736082 hasConceptScore W4311736082C89423630 @default.
• W4311736082 hasConceptScore W4311736082C94665300 @default.
• W4311736082 hasIssue "Supplement_2" @default.
• W4311736082 hasLocation W43117360821 @default.
• W4311736082 hasLocation W43117360822 @default.
• W4311736082 hasOpenAccess W4311736082 @default.
• W4311736082 hasPrimaryLocation W43117360821 @default.
• W4311736082 hasRelatedWork W1531567019 @default.
• W4311736082 hasRelatedWork W2008798949 @default.
• W4311736082 hasRelatedWork W2100067485 @default.
• W4311736082 hasRelatedWork W2351080803 @default.
• W4311736082 hasRelatedWork W2770750156 @default.
• W4311736082 hasRelatedWork W2917075906 @default.
• W4311736082 hasRelatedWork W3137961730 @default.
• W4311736082 hasRelatedWork W3178841271 @default.
• W4311736082 hasRelatedWork W4200157079 @default.
• W4311736082 hasRelatedWork W4383739282 @default.
• W4311736082 hasVolume "9" @default.
• W4311736082 isParatext "false" @default.
• W4311736082 isRetracted "false" @default.
• W4311736082 workType "article" @default.